Pharmacological FMRI in the development of new analgesic compounds

NMR in Biomedicine

Volumn 19, Issue 6, 2006, Pages 702-711

  Schweinhardt, Petra ^a,b   Bountra, Chas ^c   Tracey, Irene ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic pain; Drug development; New analgesics; Pharmacological FMRI

Indexed keywords

ANALGESIC COMPOUNDS; CHRONIC PAIN; DRUG DEVELOPMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING;

BIOMARKERS; BIOMEDICAL ENGINEERING; DRUG PRODUCTS; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT;

DRUG THERAPY;

4 AMINOBUTYRIC ACID; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; CHOLINE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GABAPENTIN; GLUTAMIC ACID; GLUTAMINE; IBUPROFEN; INOSITOL; KETAMINE; MIDAZOLAM; MU OPIATE RECEPTOR AGONIST; N ACETYLASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; REMIFENTANIL; SHORT ACTING DRUG; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON;

ARTICLE; CHRONIC PAIN; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SYNTHESIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAGNETOENCEPHALOGRAPHY; METHODOLOGY; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANALGESICS; BLOOD VOLUME; BRAIN; DRUG EVALUATION; HUMANS; MAGNETIC RESONANCE IMAGING; OXYGEN; PAIN; REGIONAL BLOOD FLOW;

EID: 33749467789     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1076     Document Type: Article

References (68)

1. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998; 280: 147-151.
2. Faucett J, McCarthy D. Chronic pain in the workplace. Nurs. Clin. N. Am. 2003; 38: 509-523.
3. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22: 1-12.
4. Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 2005; 280: 31405-31412.
5. Collins SD, Chessell IP. Emerging therapies for neuropathic pain. Expert Opin. Emerg. Drugs 2005; 10: 95-108.
6. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J. Pain Symptom Mgmt 2003; 25: S12-S17.
7. Jones AK, Derbyshire SW. Cerebral mechanisms operating in the presence and absence of inflammatory pain. Ann. Rheum. Dis. 1996; 55: 411-420.
8. Porro CA, Cavazzuti M. Functional imaging studies of the pain system in man and animals. Prog. Brain Res. 1996; 110: 47-62.
9. Scholz J, Woolf CJ. Can we conquer pain? Nat. Neurosci. 2002; 5(suppl.): 1062-1067.
10. Hill R. NKI (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmac. Sci. 2000; 21: 244-246.
11. Seymour RA, Hawkesford JE, Hill CM, Frame J, Andrews C. The efficacy of a novel adenosine agonist (WAG 994) in postoperative dental pain. Br. J. Clin. Pharmac. 1999; 47: 675-680.
12. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17.
13. Tracey I. Nociceptive processing in the human brain. Curr. Opin. Neurobiol. 2005; 15: 478-487.
14. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 2006; 5: 411-425.
15. Brooks J, Tracey I. From nociception to pain perception: imaging the spinal and supraspinal pathways. J. Anat. 2005; 207: 19-33.
16. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. Neuropimage 2000; 11: 13-23.
17. Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res. Brain Res. Rev. 2004; 44: 83-102.
18. Di Costanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M, Bonavita S, Tedeschi G, Scarabino T. High-field proton MRS of human brain. Eur. J. Radiol. 2003; 48: 146-153.
19. Salmeron BJ, Stein EA. Pharmacological applications of magnetic resonance imaging. Psychopharmac. Bull. 2002; 36: 102-129.
20. Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2006; 26: 361-372.
21. Grachev ID, Fredrickson BE, Apkarian AV. Abnormal brain chemistry in chronic back pain: an in vivo proton magnetic resonance spectroscopy study. Pain 2000; 89: 7-18.
22. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 1994; 66: 259-267.
23. Conturo TE, Lori NF, Cull TS, Akbudak E, Snyder AZ, Shimony JS, McKinstry RC, Burton H, Raichle ME. Tracking neuronal fiber pathways in the living human brain. Proc. Natl Acad. Sci. USA 1999; 96: 10422-10427.
24. Beaulieu C, Allen PS. An in vitro evaluation of the effects of local magnetic-susceptibility-induced gradients on anisotropic water diffusion in nerve. Magn. Reson. Med. 1996; 36: 39-44.
25. Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat. Neurosci. 2003; 6: 750-757.
26. Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmac. Sci. 2004; 25: 366-374.
27. Stein EA. fMRI: a new tool for the in vivo localization of drug actions in the brain. J. Anal. Toxicol. 2001; 25: 419-424.
28. Wise RG, Tracey I. The role of IMRI in drug discovery. J. Magn. Reson. Imag. 2006; Epub ahead of print.
29. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J. Clin. Pharmac. Suppl. 2001; 21S-28S.
30. Parkes LM. Quantification of cerebral perfusion using arterial spin labeling: two-compartment models. J. Magn. Reson. Imag. 2005; 22: 732-736.
31. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001; 412: 150-157.
32. Shmuel A, Augath M, Oeltermann A, Logothetis NK. Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area VI. Nat. Neurosci. 2006; 9: 569-577.
33. Arthurs OJ, Boniface S. How well do we understand the neural origins of the fMRI BOLD signal? Trends Neurosci. 2002; 25: 27-31.
34. Logothetis NK, Pfeuffer J. On the nature of the BOLD fMRI contrast mechanism. Magn. Reson. Imag. 2004; 22: 1517-1531.
35. Logothetis NK, Wandell BA. Interpreting the BOLD signal. A. Rev. Physiol. 2004; 66: 735-769.
36. Rogers R, Wise RG, Painter DJ, Longe SE, Tracey I. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004; 100: 292-301.
37. Smith SM. Overview of fMR1 analysis. In Functional MRI: An Introduction to Methods, Jezzard PMMP, Smith SM (eds). Oxford University Press: Oxford, 2001.
38. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 2004; 21: 1732-1747.
39. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey 1. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 2002; 16: 999-1014.
40. Wise RG, Lujan BJ, De Luca M, Rogers R, Tracey I. Midazolam Anxiolysis Revealed Using FMRL ISMRM: Florida, 2005.
41. Wise RG, Williams P, Tracey I. Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology 2004; 29: 626-635.
42. Hofbauer RK, Fiset P, Plourde G, Backman SB, Bushnell MC. Dose-dependent effects of propofol on the central processing of thermal pain. Anesthesiology 2004; 100: 386-394.
43. Ploghaus A, Narain C, Beckmann CF, Clare S, Bantick S, Wise R, Matthews PM, Rawlins JN, Tracey I. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci. 2001; 21: 9896-9903.
44. Ploghaus A, Tracey I, Gati JS, Clare S, Menon RS, Matthews PM, Rawlins JN. Dissociating pain from its anticipation in the human brain. Science 1999; 284: 1979-1981.
45. Tracey I, Ploghaus A, Gati JS, Clare S, Smith S, Menon RS, Matthews PM. Imaging attentional modulation of pain in the periaqueductal gray in humans. J. Neurosci. 2002; 22: 2748-2752.
46. Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I. Imaging how attention modulates pain in humans using functional MRI. Brain 2002; 125: 310-319.
47. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J. Pain 2005; 9: 463-484.
48. Peyron R, Frot M, Schneider F, Garcia-Larrea L, Mertens P, Barral FG, Sindou M, Laurent B, Mauguiere F. Role of operculoinsular cortices in human pain processing: converging evidence from PET, fMRI dipole modeling, intracerebral recordings of evoked potentials. Neuroimage 2002; 17: 1336-1346.
49. Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci. 2002; 3: 655-666.
50. Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting interoceptive awareness. Nat. Neurosci. 2004; 7: 189-195.
51. Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LL, Parvizi J, Hichwa RD. Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat. Neurosci. 2000; 3: 1049-1056.
52. Iannetti GD, Niazy RK, Wise RG, Jezzard P, Brooks JC, Zambreanu L, Vermart W, Matthews PM, Tracey I. Simultaneous recording of laser-evoked brain potentials and continuous, high-field functional magnetic resonance imaging in humans. Neuroimage 2005; 28: 708-719.
53. Bomhovd K, Quante M, Glauche V, Bromm B, Weiller C, Buchel C. Painful stimuli evoke different stimulus-response functions in the amygdala, prefrorital, insula and somatosensory cortex: a single-trial fMRI study. Brain 2002; 125: 1326-1336.
54. Coghill RC, Sang CN, Maisog JM, ladarola MJ. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J. Neurophysiol. 1999; 82: 1934-1943.
55. Craig AD, Chen K, Bandy D, Reiman EM. Thermosensory activation of insular cortex. Nat. Neurosci. 2000; 3: 184-190.
56. Derbyshire SW, Jones AK, Gyulai F, Clark S, Townsend D, Firestone LL. Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain 1997; 73: 431-445.
57. Peyron R, Garcia-Larrea L, Gregoire MC, Costes N, Convers P, Lavenne F, Mauguiere F, Michel D, Laurent B. Haernodynamic brain responses to acute pain in humans: sensory and attentional networks. Brain 1999; 122(Pt 9): 1765-1780.
58. PorTo CA, Cettolo V, Francescato MP, Baraldi P. Temporal and intensity coding of pain in human cortex. J. Neurophysiol. 1998; 80: 3312-3320.
59. Schweinhardt P, Glynn C, McQuay H, Jack T, Chessell 1, Bountra C, Tracey I. An fMRI study of cerebral processing of brush-evoked allodynia in neuropathic pain patients. Neuroimage 2006; Epub ahead of print.
60. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-60T
61. Koeppe C, Schneider C, Thierne K, Mense S, Stratz T, Muller W, Flor H. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand. J Rheumatol. Suppl. 2004; 24-27.
62. Johansen-Berg H, Dawes H, Guy C, Smith SM, Wade DT, Matthews PM. Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. Brain 2002; 125(Pt 12): 2731-2742.
63. Pleger B, Tegenthoff M, Ragert P, Forster AF, Dinse HR, Schwenkreis P, Nicolas V, Maier C. Sensorimotor retuning [corrected] in complex regional pain syndrome parallels pain reduction. Ann. Neurol. 2005; 57: 425-429.
64. Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Cortical reorganization during recovery from complex regional pain syndrome. Neurology 2004; 63: 693-701.
65. Flor H, Elbert T, Knecht S, Wienbruch C, Pantev C, Birbaumer N, Larbig W, Taub E. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation. Nature 1995; 375: 482-484.
66. Parkes LM, Bastiaansen MC, Norris DG. Combining EEG. fMRI to investigate the post-movement beta rebound. Neuroimage 2006; 29: 685-696.
67. Stroman PW, Tomanek B, Krause V, Frankenstein UN, Malisza KL. Mapping of neuronal function in the healthy and injured human spinal cord with spinal fMRI. Neuroimage 2002; 17: 1854-1860.
68. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, Vermart W, Tracey I. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc. Natl Acad. Sci. USA 2005; 102: 18195-18200.